54,600 Shares in Inhibikase Therapeutics, Inc. (NYSE:IKT) Acquired by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp bought a new position in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) during the 4th quarter, HoldingsChannel.com reports. The fund bought 54,600 shares of the company’s stock, valued at approximately $177,000.

Several other large investors have also recently added to or reduced their stakes in IKT. Stifel Financial Corp purchased a new stake in shares of Inhibikase Therapeutics in the 4th quarter valued at approximately $43,000. Nantahala Capital Management LLC purchased a new stake in shares of Inhibikase Therapeutics in the 4th quarter valued at approximately $7,118,000. Blackstone Inc. purchased a new stake in shares of Inhibikase Therapeutics in the 4th quarter valued at approximately $6,730,000. Barclays PLC purchased a new stake in shares of Inhibikase Therapeutics in the 4th quarter valued at approximately $273,000. Finally, Fairmount Funds Management LLC purchased a new stake in shares of Inhibikase Therapeutics in the 4th quarter valued at approximately $19,906,000. 3.81% of the stock is owned by hedge funds and other institutional investors.

Inhibikase Therapeutics Price Performance

NYSE IKT opened at $1.99 on Wednesday. The firm’s fifty day moving average price is $2.09 and its 200 day moving average price is $2.48. The company has a market capitalization of $147.94 million, a price-to-earnings ratio of -0.75 and a beta of 1.01. Inhibikase Therapeutics, Inc. has a 12 month low of $1.12 and a 12 month high of $4.20.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “neutral” rating on shares of Inhibikase Therapeutics in a research report on Friday, March 28th.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.